Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. It offers a diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. The Company's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney disease, orthopedic spine conditions, and cardiovascular disorders.
Market capitalization (1-Oct-2021)
Closing stock price (1-Oct-2021)
Mesoblast has 3.97k Twitter Followers. The number of followers has increased 0.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Mesoblast founded?
Mesoblast was founded in 2004.
Who are Mesoblast key executives?
Mesoblast's key executives are Silviu Itescu, Joseph R. Swedish and Josh Muntner.
How many employees does Mesoblast have?
Mesoblast has 102 employees.
Who are Mesoblast competitors?
Competitors of Mesoblast include Celltex, AXON Neuroscience and Human Stem Cells Institute.
Where is Mesoblast headquarters?
Mesoblast headquarters is located at Level 38/55 Collins St, Melbourne.
Where are Mesoblast offices?
Mesoblast has offices in Melbourne, New York and Singapore.
How many offices does Mesoblast have?
Mesoblast has 3 offices.
Receive alerts for 300+ data fields across thousands of companies